Long-Term Effects of Secukinumab on Fatigue in Ankylosing Spondylitis
Study authors assessed the long-term effects of secukinumab on fatigue in patients with ankylosing spondylitis in the MEASURE 1 and MEASURE 2 trials.
Study authors assessed the long-term effects of secukinumab on fatigue in patients with ankylosing spondylitis in the MEASURE 1 and MEASURE 2 trials.
Investigators compared differences in pain reports between patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis to assess how pain sensitivity was associated with disease and health outcomes.
Investigators examined the long-term association between disease activity and disability in axSpA.
Researchers evaluated the prevalence of axial involvement in early peripheral spondyloarthritis and whether inflammation predicted relapse on treatment withdrawal.
Study authors determined the association between disease activity and the subsequent 2-year spinal radiographic progression in axial spondyloarthritis.
The FDA has accepted for review the BLA for AVT02 (Alvotech), a proposed biosimilar to adalimumab; AbbVie, with high concentration (100mg/mL) dosage forms.
Researchers evaluated the safety and efficacy of tofacitinib for the treatment of patients with ankylosing spondylitis.
Study authors evaluated the prevalence of axial spondyloarthritis in patients with inflammatory bowel disease in secondary care.
Researchers assessed whether the gut microbiome in ankylosing spondylitis and inflammatory bowel disease was different, and whether it correlated with disease activity.
Researchers evaluated the effect of ixekizumab on self-reported functioning and health in patients with active nonradiographic axial spondyloarthritis.